David P. Meeker serves as the Chief Executive Officer at Rhythm Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity. With an extensive background in the pharmaceutical industry, Meeker has been instrumental in leading Rhythm Pharmaceuticals through various stages of growth and development. Under his leadership, the company has advanced its mission to address unmet medical needs in the field of rare genetic diseases. Prior to joining Rhythm Pharmaceuticals, Meeker held significant leadership positions at other notable companies in the healthcare sector. He was the President and CEO of Genzyme Corporation, where he played a pivotal role in expanding the company's global presence and portfolio of treatments for rare diseases. His strategic vision and operational expertise were key factors in driving Genzyme's success. Meeker also spent over a decade at Merck & Co., where he held various senior management roles, further solidifying his reputation as a seasoned executive in the pharmaceutical industry. At Rhythm Pharmaceuticals, Meeker's primary responsibilities include overseeing the company's strategic direction, operational execution, and the advancement of its clinical programs. His leadership has been crucial in navigating the company through the complexities of drug development and regulatory processes. Meeker's commitment to improving the lives of patients with rare genetic disorders aligns with Rhythm Pharmaceuticals' core mission, making him a vital asset to the organization as it continues to grow and innovate in the field of rare disease therapeutics.